ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 953

Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data

Robin Dore1, Lawrence Chang 2, Yuanyuan Ji 3, Suying Li 3, Jenya Antonova 2 and Mark Genovese 4, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3Chronic Disease Research Group, Minneapolis, MN, 4Stanford University, Stanford, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Disease-modifying antirheumatic drugs, Medicare, Rheumatoid arthritis (RA), treatment and Biologics

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S089: Health Services Research I: Clinical Perspectives (951–956)

Session Type: ACR/ARP Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: In RA patients not meeting treat-to-target goals despite treatment with a biologic (b)DMARD, ACR guidelines1 recommend using other targeted immunomodulators (TIM): TNF-α inhibitor (TNFi), non-TNFi biologic (b)DMARDs, or a Janus kinase inhibitor (JAKi). Understanding treatment disposition and persistency can help optimize next treatment selection among Medicare recipients who initiated first bDMARD. We described treatment patterns and persistency in Medicare RA patients on first bDMARD.

Methods: In 20% sample of Medicare fee-for-service beneficiaries, the study population comprised RA patients (≥1 RA claims + ≥1 DMARD claims) who initiated (index date) their first bDMARD between 01/2012 and 12/2015 (no bDMARD use ≥12 months pre-index), without cancer or non-RA autoimmune disease. Subsequent treatment patterns were described during a follow-up period ending 12/2016, with censoring at death or end of Medicare coverage. Patients were grouped as Persisters (persisted on their first bDMARD) or Non-Persisters (did not persist), the latter being divided into Switchers (switched to another TIM), Restarters (restarted the first bDMARD after a gap), and Stoppers (stopped TIMs altogether). Persistency loss was estimated through Kaplan-Meier time-to-event analysis, with the event being discontinuation or first gap in initial bDMARD coverage exceeding 60 days past next-refill due date. Persistency was estimated for all patients and stratified by Non-Persisters, and then further by Switchers, Restarters, Stoppers.

Results: The sample of 10,314,539 enrollees contained 154,311 RA patients, including 21,012 patients initiating bDMARD (52% intravenous, 48% subcutaneous): 79% female with mean age 66 years (Table). The sample consisted of 1,012 (4.8%) Persisters, 5,723 (27.2%) Switchers, 4,705 (22.4%) Restarters, and 9,572 (45.6%) Stoppers (Figure 1). Among all bDMARD initiators, 22.0% lost persistency by month 2 and 56.0% by month 12 (Figure 2a). Within Non-Persisters, the probability of losing persistency at month 12 was 58.9% overall, 72.4% for Switchers, 73.0% for Restarters, and 43.8% for Stoppers (Figure 2b). Among Non-Persisters, incident events peaked at months 1, 3, 6, 9, 12, 24, 36, 48, and 60; with contributions to persistency loss similar for all groups until month 12, after which Stoppers largely drove ongoing loss of persistency (Figure 2b, c).

Conclusion: After initiating their first bDMARD, Medicare beneficiaries with RA experienced substantial treatment interruptions, demonstrating deviations from the standard treatment-escalation approach described in the ACR guidelines. Over half the patients lost persistency on first bDMARD by year 1. Moreover, almost half of those who lost persistency on first bDMARD remained off TIM therapy altogether, suggesting a substantial unmet need for treatment in this patient population that warrants further investigation.

References

  1. Singh JA, et al. Arthritis Rheumatol 2016;68:1-26.


Table


Figure 1


Figure 2


Disclosure: R. Dore, AbbVie, 2, 5, 8, AbbVie, Inc., 5, 8, 9, Abbvie, Inc., 2, 5, 8, Amgen, 2, 5, 8, 9, Biogen, 2, 9, Gilead Science, 2, 5, Gilead Sciences, Inc., 2, 5, 9, Lilly, 2, 5, 8, 9, Novartis, 2, 5, 9, Pfizer, 2, 8, 9, Radius, 8, Regeneron, 8, Sanofi, 8, UCB, 2, 8, 9, VCB, 8; L. Chang, Gilead Science, 9, Gilead Sciences, Inc., 1, 3, Lilly, 9; Y. Ji, None; S. Li, None; J. Antonova, Gilead Science, 1, 3, Gilead Sciences, Inc., 1, 3; M. Genovese, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Inc., 9, Astellas, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, EMD Merck Serono, 2, 5, Galapagos, 2, 5, Galapagos NV, 2, 5, 9, Genentech/Roche, 2, 5, Gilead, 2, 5, Gilead Science, 9, Gilead Sciences, Inc., 2, 5, 9, GSK, 5, Lilly, 2, 5, 9, Novartis, 2, 5, Pfizer, 2, 5, 9, Pfizer Inc, 2, 5, Pfizer, Inc., 9, Pzier, 9, RPharm, 5, Sanofi Genzyme, 2, 5, Vertex, 2, 5.

To cite this abstract in AMA style:

Dore R, Chang L, Ji Y, Li S, Antonova J, Genovese M. Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/treatment-patterns-and-persistency-following-the-first-biologic-dmard-in-patients-with-rheumatoid-arthritis-real-world-analysis-of-2012-2016-us-medicare-data/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-patterns-and-persistency-following-the-first-biologic-dmard-in-patients-with-rheumatoid-arthritis-real-world-analysis-of-2012-2016-us-medicare-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology